

Docket No. 10806-133


CERTIFICATE OF EXPRESS MAILING

PATENT

Express label #: EL378851644US

Date of Deposit: June 29, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box CPA; Assistant Commissioner for Patents; Washington, DC 20231.



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Anders Berkenstam et al : Paper No.:
Serial No.: To be assigned : Group Art Unit:
Filing Date: June 29, 2001 : Examiner:
For: **Screening Methods**

PRELIMINARY AMENDMENT

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to calculation of the filing fee and first action by the Examiner, please amend the present application as follows:

In the Claims:

Please cancel claim 12.

Please amend claims 6, 10, 11, 13 and 14 to read as follows:

6. (Amended) A cultured host cell harboring a vector according to claim 4.

10. (Amended) A method for identifying an agent useful for stimulating the biological activities of a mammalian IPAS polypeptide, said method comprising the steps

(i) contacting a candidate agent with the mammalian IPAS polypeptide according to claim 2; and

09896791-062901

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide.

11. (Amended) A method for identifying an agent useful for the inhibition of angiogenesis and/or tumor growth, said method comprising the steps

(i) contacting a candidate agent with a mammalian IPAS polypeptide according to claim 2; and

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide, such stimulation being indicative for an agent useful for the treatment of a medical condition related to angiogenesis and/or tumor growth.

13. (Amended) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 8.

14. (Amended) The use or method according to claim 12, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases.

Please add the following claims 15-21:

--15. (New) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 9. --

--16. (New) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 10. --

--17. (New) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 11. --

--18. (New) A cultured host cell harboring a vector according to claim 5. --

--19. (New) The use or method according to claim 15, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases. --


--20. (New) The use or method according to claim 16, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases. --

--21. (New) The use or method according to claim 17, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases. --

REMARKS

By the present Amendment, the claims are amended to omit their multiple dependency. A Version with Markings Showing Changes Made is attached. Claims 15-21 are added. Support for claims 15-17 may be found in original claim 13, support for claim 18 may be found in original claim 6 and support for claims 19-21 may be found in original claim 14. It is believed that these changes do not involve any introduction of new matter, whereby entry is believed to be in order.

Respectfully submitted,



Holly D. Kozlowski
Registration No. 30468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

692503.01

VERSION WITH MARKINGS SHOWING CHANGES MADE

6. (Amended) A cultured host cell harboring a vector according to claim 4 [or 5]. An injector device for delivery of liquid from a high pressure source, the device comprising

10. (Amended) A method for identifying an agent useful for stimulating the biological activities of a mammalian IPAS polypeptide, said method comprising the steps

(i) contacting a candidate agent with the mammalian IPAS polypeptide according to claim 2 [or 3]; and

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide.

11. (Amended) A method for identifying an agent useful for the inhibition of angiogenesis and/or tumor growth, said method comprising the steps

(i) contacting a candidate agent with a mammalian IPAS polypeptide according to claim 2 [or 3]; and

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide, such stimulation being indicative for an agent useful for the treatment of a medical condition related to angiogenesis and/or tumor growth.

13. (Amended) A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to claim 8 [any one of claims 8 to 11].

14. (Amended) The [use or] method according to claim [12 or] 13, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases.

106290 T629689